Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)

NCT03536754 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03536754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03536754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
May 17, 2018
Completion date
February 19, 2020
Enrollment
46 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis, fsgs, glomerulosclerosis